FibroGen to Report Third Quarter 2016 Financial Results on November 8, 2016
01 nov. 2016 17h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, Nov. 01, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel...
FibroGen Completes Enrollment in Roxadustat Phase 3 Studies in China
31 oct. 2016 08h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, Oct. 31, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company, today reported completion of enrollment in its Phase 3 clinical trials in...
FibroGen Reports Financial Results for the Second Quarter of 2016
08 août 2016 16h02 HE
|
FibroGen, Inc.
Enrollment Completed in Placebo-Controlled Study of FG-3019 (Pamrevlumab) in IPF China Phase 3 Top Line Data Expected by Year-End 2016 –Webcast Conference Call Scheduled for 4:30pm EDT Today– ...
FibroGen to Report Second Quarter 2016 Financial Results on August 8, 2016
02 août 2016 20h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, Aug. 02, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Astellas and FibroGen Announce First Patient Treated in Phase 3 Studies and Positive Phase 2 Results of Roxadustat in Patients with Chronic Kidney Disease in Japan
25 juil. 2016 21h00 HE
|
FibroGen, Inc.
TOKYO and SAN FRANCISCO, July 25, 2016 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE:4503) (“Astellas”) and FibroGen, Inc. (Nasdaq:FGEN) (“FibroGen”), today announced the dosing of the first...
Promising Phase 2 Data Show Roxadustat Corrected Anemia in Chronic Kidney Disease Patients Before Intervention with Dialysis
20 avr. 2016 23h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, April 20, 2016 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq:FGEN) (“FibroGen”), a research-based biopharmaceutical company, today announced that the Clinical Journal of the American...